The overall sentiment shows agreement on the device’s safety and effectiveness, with posts like 'effective at anatomic closure' and 'low incidence of adverse events’ demonstrating support. Engagement is high due to detailed sharing of primary outcome data, such as success rates and complication incidences, which underscores the relevance and potential impact of the study’s findings within the medical community.
AgreementModerate agreement
Most discussions express positive support for the publication, emphasizing its safety and effectiveness, indicating general agreement with the findings.
InterestModerate interest
The discussions show a moderate level of interest, with frequent mentions of the trial results and their potential significance, but limited in-depth analysis.
EngagementHigh engagement
Numerous posts engage deeply by sharing specific data points like implant success rates and adverse events, reflecting active interpretation and validation of the study.
ImpactHigh impact
The posts suggest the study could influence clinical practice and future research, highlighting the importance of the device and its promising safety profile.
Abstract in brief
The WATCHMAN FLX device offers a non-drug option for reducing thromboembolic risks in patients with nonvalvular atrial fibrillation, approved for use in the U.S. since 2015.
In a study involving 400 patients, the device demonstrated a very low safety event rate of 0.5% and achieved effective LAA closure in 100% of cases at a 12-month follow-up.
Overall, the findings suggest that the WATCHMAN FLX is both safe and effective, making it a viable alternative to traditional oral anticoagulants for eligible patients.
PINNACLE FLX is now online @CircAHA
Single arm study of 400 patients:
❇️ Implant success = 98.8%
❇️ Device embolization = 0%
❇️ Pericardial effusion = 1%
❇️ Leak >5mm = 0%
❇️ Device thrombus = 1.7%
7 cases; 4 seen on planned TEE {1 at 45 day & 3 at 1 yr}
https://t.co/YkqGVrxpVR https://t.co/yTZt6u7fcI
Now published in @CircAHA : 12-month results from the PINNACLE FLX trial: https://t.co/sF6vIRmQmg
Safety info: https://t.co/6r0sVPhT6J https://t.co/zcVvECrSQ4
In PINNACLE FLX trial, the next generation Watchman LAA closure device was found to be effective at anatomic closure with a low incidence of adverse events. Read more: https://t.co/sXPQFVPGWh #AHAJournals @davidrholmes2 @jstone38801 @josoriomd https://t.co/meOYTSSyoq
May 4, 2021 · 11 likes · 7 shares · 77,717 followersView post →
BC
BostonSci Cardiology
@BSCCardiology · X
See the newly published 12-month data from the PINNACLE FLX trial, now available via @CircAHA: https://t.co/pGiKQIng8f
Safety info: https://t.co/hCEsphE5Cs https://t.co/ObZW9aKE1A
Primary Outcome Evaluation of a Next Generation Left Atrial Appendage Closure Device: Results from the PINNACLE FLX Trial
https://t.co/C4wrAo5imy
@mirvatalasnag @MarcoJe80135689 @gregoirerange @PresidentCNCH @EAPCIPresident @CNCHcollege https://t.co/uhpmfjt5im
This episode discusses the evolving evidence behind left atrial appendage occlusion, reviewing pivotal trials like PROTECT, PREVAIL, and the upcoming CHAMPIONAF at ACC 2026, highlighting safety, efficacy, and future…
This week, John Mandrola MD discusses three key aspects of the recent AF guidelines, emphasizing early rhythm-control therapy's potential to reduce cardiovascular risks. Join us for an in-depth analysis of the latest…
RT @CircAHA: Next, Corresponding Author, Dr. Saibal Kar, and Associate Editor, Dr. Mark Link, discuss LAA Closure PINNACLE FLX Trial
Articl…
May 10, 2021 · 4 shares · 2,445 followersView post →
C
Circulation
@CircAHA · X
Next, Corresponding Author, Dr. Saibal Kar, and Associate Editor, Dr. Mark Link, discuss LAA Closure PINNACLE FLX Trial
Article: https://t.co/Dsjs9apI88
Listen here: https://t.co/YY7pYrTrTz #AHAJournals https://t.co/kFD14pMLwW
May 10, 2021 · 5 likes · 4 shares · 77,717 followersView post →
にM
にゅろ, MD
@EBNeuro · X
2021/5/4 出版分 twitterでバズった論文 神経分野
Primary Outcome Evaluation of a Next Generation Left Atrial Appendage Closure Device: Results from the PINNACLE FLX Trial
https://t.co/L6OdyY2N43
Tweets: 65
In PINNACLE FLX trial, the next generation Watchman LAA closure device was found to be effective at anatomic closure with a low incidence of adverse events. Read more: https://t.co/sXPQFVPGWh #AHAJournals @davidrholmes2 @jstone38801 @josoriomd https://t.co/meOYTSSyoq
May 4, 2021 · 11 likes · 7 shares · 77,717 followersView post →
A
Archigen
@Archigensrl · X
RT @BSCCardiology: See the newly published 12-month data from the PINNACLE FLX trial, now available via @CircAHA: https://t.co/pGiKQIng8f…
See the newly published 12-month data from the PINNACLE FLX trial, now available via @CircAHA: https://t.co/pGiKQIng8f
Safety info: https://t.co/hCEsphE5Cs https://t.co/ObZW9aKE1A
I am pleased to announce the much-anticipated publication in @CircAHA of the Primary Endpoint results from the PINNACLE FLX Trial; Primary Outcome Evaluation of a Next Gen #LAAclosure #ahajournals #LAAC @CViScottsdale https://t.co/6wCR8aBSaC
#ICYMI Dr. Saibal Kar et al have published the “Primary Outcome Evaluation of a Next Generation Left Atrial Appendage Closure Device: Results from the PINNACLE FLX Trial” in @CircAHA: https://t.co/24kuoWBrVv
Safety info: https://t.co/GEsbWSImjy https://t.co/tDbzzDkUyU
Primary Outcome Evaluation of a Next Generation Left Atrial Appendage Closure Device: Results from the PINNACLE FLX Trial
https://t.co/C4wrAo5imy
@mirvatalasnag @MarcoJe80135689 @gregoirerange @PresidentCNCH @EAPCIPresident @CNCHcollege https://t.co/uhpmfjt5im
PINNACLE FLX is now online @CircAHA
Single arm study of 400 patients:
❇️ Implant success = 98.8%
❇️ Device embolization = 0%
❇️ Pericardial effusion = 1%
❇️ Leak >5mm = 0%
❇️ Device thrombus = 1.7%
7 cases; 4 seen on planned TEE {1 at 45 day & 3 at 1 yr}
https://t.co/YkqGVrxpVR https://t.co/yTZt6u7fcI
Now published in @CircAHA : 12-month results from the PINNACLE FLX trial: https://t.co/sF6vIRmQmg
Safety info: https://t.co/6r0sVPhT6J https://t.co/zcVvECrSQ4
Left atrial appendage occlusion: Contemporary review and current ...
News
prevention in atrial fibrillation: Current status and doi: 10.1161/CIRCULATIONAHA.120.050117 perspectives. Eur Heart J. 2024;45(32):2914-2932. 19. Reddy VY ...
https://doi.org/10.1161/CIRCULATIONAHA.114.010999 103:41–9. https://doi.org ... 120.050117. Freixa X. Rationale and design of a randomized clinical ...
MA
BC
C
AM
JS
JH
にM
E
A
С
C
CR
N
PP
PM
AM
RC
PG
TB
CH
P
DA
I
DS
MI
HJ
JF
RS
IB
AF
DC
RM
KS
ER
IB
MR
IN
OB
SL
S
SM
RE
SM
NV
SM
SN
OF
AM
HS
AR
B
AM